about
Optimizing the use of antithrombotic therapy for atrial fibrillation in older people: a pharmacist-led multidisciplinary interventionA review of the safety of anticoagulants in older people using the medicines management pathway: weighing the benefits against the risksSafe use of antithrombotics for stroke prevention in atrial fibrillation: consideration of risk assessment tools to support decision-makingAdherence to medication for the treatment of psychosis: rates and risk factors in an Ethiopian populationA systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care settingA cluster-randomized controlled trial of a computerized antithrombotic risk assessment tool to optimize stroke prevention in general practice: a study protocol.Preparing pharmacists to deliver a targeted service in hypertension management: evaluation of an interprofessional training program.A Community Health Worker-Based Program for Elderly People With Hypertension in Indonesia: A Qualitative Study, 2013.Applying the emergency risk management process to tackle the crisis of antibiotic resistance.Self-medication among people living with hypertension: a review.Contemporary approaches to managing atrial fibrillation: A survey of Australian general practitioners.Understanding the reasons behind the low utilisation of thrombolysis in strokeOld age, high risk medication, polypharmacy: a 'trilogy' of risks in older patients with atrial fibrillation.Implementation and evaluation of a pharmacist-led hypertension management service in primary care: outcomes and methodological challenges.Optimizing Stroke Prevention in Patients With Atrial Fibrillation: A Cluster-Randomized Controlled Trial of a Computerized Antithrombotic Risk Assessment Tool in Australian General Practice, 2012-2013.Educating patients about warfarin therapy using information technology: A survey on healthcare professionals' perspectivesUtilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.Targeting suboptimal prescribing in the elderly: a review of the impact of pharmacy services.Using scenarios to test the appropriateness of pharmacist prescribing in asthma management.Drug Burden Index and potentially inappropriate medications in community-dwelling older people: the impact of Home Medicines Review.Use of evidence-based therapy for the prevention of cardiovascular events among older people.Retrospective evaluation of home medicines review by pharmacists in older Australian patients using the medication appropriateness index.Clinical outcomes of a collaborative, home-based postdischarge warfarin management service.Barriers to the utilization of thrombolysis for acute ischaemic stroke.Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA).Challenges of older patients' knowledge about warfarin therapy.New oral anticoagulants in practice: pharmacological and practical considerations.Use of medications for secondary prevention in stroke patients at hospital discharge in Australia.The potential role for a pharmacist in a multidisciplinary general practitioner super clinic.Pharmacotherapy in the ageing patient: The impact of age per se (A review).Impact of a Computerized Antithrombotic Risk Assessment Tool on the Prescription of Thromboprophylaxis in Atrial Fibrillation.Medication safety in neonatal care: a review of medication errors among neonates.A global perspective of the roles of the pharmacist in the NICU.Factors Affecting Patients' Perception On, and Adherence To, Anticoagulant Therapy: Anticipating the Role of Direct Oral Anticoagulants.Review of drug utilization patterns in NICUs worldwide.Pilot of a Computerised Antithrombotic Risk Assessment Tool Version 2 (CARATV2.0) for stroke prevention in atrial fibrillation.Balancing risk versus benefit: the elderly patient's perspective on warfarin therapyAssessment of Web-based education resources informing patients about stroke prevention in atrial fibrillation.Utilization of antithrombotic therapy for stroke prevention in atrial fibrillation: a cross-sectional baseline analysis in general practice.Warfarin management after discharge from hospital: a qualitative analysis.
P50
Q28193225-2FF53917-E88F-4587-96A5-509B3E602A1FQ33949244-80E617C0-AF24-46B9-B130-67B4090CC1AAQ33949571-64FEC3FF-B181-4967-A159-AA5CC0E97053Q34308009-4455B24A-39CE-4515-953F-61458F14202BQ34637462-3C077A25-B133-47AE-BC4E-25776A1FCE59Q35089113-9741474E-3F74-45B3-A6C2-B2301C789CEFQ35790832-0E1751D4-AB72-44CD-BF4F-B60A1EE3E3DDQ35808826-A2CDF1AA-0A29-4EC8-A8B2-716D02E0C85CQ36026058-677A9167-BD10-4900-9A15-EAB707FFCA16Q36260462-9241DB1A-6EEC-4D9B-AC55-0F21A2007A81Q36360590-B929A3C6-016F-42BE-A367-D07C17946208Q36764851-A078C6B0-7CF9-4BAD-9434-A198E7531A67Q37060185-7A93B903-2EE8-4740-AFA5-8942D022DF78Q37060189-9F3EF9B3-F23E-44CB-BE71-B8F552A56DC8Q37109120-01FAD1E0-A0F4-4108-880E-D704CB7B8A9BQ37190871-DF781A47-D708-44C0-A943-26A7918C8A27Q37366808-6C7383AF-EAA8-4CF4-B8A4-9352CBE12C17Q37496385-E0FE45D6-AF19-43F3-AC6F-D964341AE4BBQ37640291-3C2EADCB-6559-4848-B080-009DA68D1A5BQ37682218-C3F6F774-7CD8-40BD-AA84-E3D056CED4F3Q37783853-36E10400-232E-4B88-88A7-C76ABDDA3157Q37813891-1379C96C-1C5A-42ED-8989-C15AC99A4E4DQ37850886-452EAB40-DC56-48E6-9AE7-E14CE608FC64Q37989982-2995E8C3-FE7F-4F58-8C3E-20919A168507Q38019575-EE3B598A-EC48-43E3-B042-3332ED569DF4Q38117337-F6914A25-0C62-47EF-B8BC-6A48DBE4D115Q38180988-3ABC6D2E-CA9C-4099-8B33-C1F2774CABACQ38187373-2352094B-E37E-4B2D-896C-FC0556C15380Q38391641-1183C534-D35A-4E94-B36B-11F7099B3603Q38557533-150B27A1-9A98-4B6B-800E-9DD701080931Q38817424-5E9ED709-0186-4B13-9604-AF12B7F3164FQ38864533-3CF41802-1EAC-4C75-9BB8-315E103BD965Q38871087-87E91208-3F66-4A0C-970E-AC622129ACC3Q38903357-6BDD6F77-54D2-4384-AFB1-B608D9775B51Q38942041-59D4B178-539A-42CF-9A3C-2777DD1D94DFQ39029953-BAEC1DF9-6852-4398-BE54-634531A1BC9FQ39209467-B23ECF8F-439F-4461-BBB0-69417ACAD959Q39321699-C9910544-6A9F-45E7-9AE0-B2E3C3304A81Q39659827-0F5F457E-8CD1-44AF-AAE5-EB25530988A0Q39695078-1FFB00B9-92C0-4534-AE7E-B7C785A0D6C2
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Beata V Bajorek
@ast
Beata V Bajorek
@en
Beata V Bajorek
@es
Beata V Bajorek
@nl
Beata V Bajorek
@sl
type
label
Beata V Bajorek
@ast
Beata V Bajorek
@en
Beata V Bajorek
@es
Beata V Bajorek
@nl
Beata V Bajorek
@sl
altLabel
Beata Violeta Bajorek
@en
prefLabel
Beata V Bajorek
@ast
Beata V Bajorek
@en
Beata V Bajorek
@es
Beata V Bajorek
@nl
Beata V Bajorek
@sl
P106
P21
P31
P496
0000-0002-2532-7187